Viewing Study NCT01222195

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 1:41 PM
Ignite Modification Date: 2026-02-07 @ 5:25 PM
Study NCT ID: NCT01222195
Status: TERMINATED
Last Update Posted: 2012-08-07
First Post: 2010-10-14
Is Gene Therapy: True
Has Adverse Events: True
Brief Title: Lenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS)
Sponsor: M.D. Anderson Cancer Center
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Leukemia View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Myelodysplastic Syndrome View
None Red cell transfusion independence View
None Darbepoetin alfa View
None Lenalidomide View
None CC-5013 View
None Revlimid View
None Aranesp View
None Erythropoietin View
None Erythropoiesis Stimulating Protein View